ArticleMolecular biology reports2025
Streptomyces sp. strain CENK12 from Centella Asiatica L.: a potential source of antimicrobial and antioxidant agents against multidrug-resistant Staphylococcus aureus.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCentella asiatica L. plays a significant role in the traditional medicine of the Indigenous Mizo communities, valued for its healing abilities, especially in addressing wounds, skin ailments, and gastrointestinal issues. METHODS AND
resultsThis study aims to isolate a potential endophytic actinobacteria from Centella asiatica L. with antimicrobial and antioxidant properties. Initially, five endophytic actinobacterial strains were isolated from Centella asiatica using ISP7 as a growth medium. CENK12 was the most promising isolate, inhibiting 11 out of 15 clinical multidrug-resistant Staphylococcus aureus (MDRSA) pathogens using agar well diffusion method. Scanning electron microscopy (SEM) revealed its morphology and 16 S rRNA sequencing identified it as Streptomyces sp. strain CENK12. Phytochemicals such as phenols and flavonoids, which have been reported in the host plant Centella asiatica, were also quantified in the endophytic Streptomyces sp. The results showed the presence of both phenols and flavonoids. The total phenolic content was 68.6 ± 0.51 mg of Gallic Acid Equivalent (GAE) for every gram of extract, and the total flavonoid content was 10.92 ± 0.64 mg of Quercetin (QE) for every gram of the extract. Antioxidant activity, assessed using ABTS method and DPPH assay and revealed an antioxidant capacity of IC50 = 82.78 µg/ml and IC50 = 668.3 ± 0.92 µg/mL for ABTS and DPPH assay respectively. GC-MS analysis detected 20 volatile organic compounds. Additionally, chromatographic analysis of the methanol fraction was conducted using high-performance thin-layer chromatography (HPTLC) with two optimized solvent systems designed for glycosides and phenols: Ethyl acetate, methanol, and water in a ratio of 20:3:2, and cyclohexane, ethyl acetate, and formic acid in a ratio of 4:6:1.
conclusionThis study provides a strong evidence that Streptomyces sp. (CENK12) is a promising agent for the development of new drug that could fight multidrug-resistant Staphylococcus aureus (MDRSA) and moreover its potent antioxidant activity suggests its potential as a novel antioxidants agent.
Indexed as
Identifiers
40856869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.